La cadena de opciones muestra datos clave de las opciones de acciones de Ironwood Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Ironwood Pharmaceuticals..

Ironwood Pharmaceuticals (NASDAQ:IRWD) Bolsa, Cadena de Opciones

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals Inc

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares increased by 8.8% to $0.3 during Tuesday's after-market session. The market value of their outstanding shares is at $18.8 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock rose 8.14% to $0.69. The market value of their outstanding shares is at $111.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 8.0% to $0.88. The company's market cap stands at $14.5 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock moved upwards by 7.77% to $0.97. The company's market cap stands at $14.7 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 6.66% to $1.12. The market value of their outstanding shares is at $2.3 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 6.36% to $0.33. The market value of their outstanding shares is at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 26.2% to $2.14 during Tuesday's after-market session. The market value of their outstanding shares is at $77.5 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) stock decreased by 16.76% to $3.08. The company's market cap stands at $204.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock decreased by 16.26% to $0.24. The company's market cap stands at $20.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 14.35% to $5.97. The market value of their outstanding shares is at $17.2 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares declined by 8.28% to $0.75. The market value of their outstanding shares is at $17.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 6.89% to $4.8. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACXP

BMEA

CGTX

CRDF

EYEN

GOVX

HSDT

IBIO

IRWD

SLRX

XAIR

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock rose 15.2% to $0.71 during Friday's after-market session. The company's market cap stands at $115.5 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock increased by 10.45% to $3.91. The company's market cap stands at $756.9 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares rose 6.93% to $3.7. The company's market cap stands at $69.5 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) stock moved upwards by 6.62% to $0.77. The company's market cap stands at $59.9 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) stock rose 6.35% to $0.34. The company's market cap stands at $14.3 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares rose 5.93% to $0.19. The company's market cap stands at $24.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock declined by 10.4% to $0.02 during Friday's after-market session. The company's market cap stands at $7.3 million. </li>
<li>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) shares fell 9.17% to $1.09. The market value of their outstanding shares is at $327.0 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares declined by 8.7% to $0.32. The company's market cap stands at $10.0 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 8.22% to $0.45. The market value of their outstanding shares is at $2.1 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) stock declined by 7.08% to $1.05. The company's market cap stands at $34.7 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 7.07% to $6.05. The market value of their outstanding shares is at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

BMGL

CLDI

ENTO

HCTI

HYPR

JUNS

PACB

RLYB

SSII

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares rose 32.5% to $0.38 during Friday's after-market session. The market value of their outstanding shares is at $2.2 million. As per the press release, Q1 earnings came out today. </li>
<li>Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) shares rose 15.99% to $34.38. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) stock moved upwards by 10.52% to $16.49. The company's market cap stands at $1.4 billion. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) shares moved upwards by 10.16% to $0.66. The market value of their outstanding shares is at $106.8 million. </li>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) stock rose 8.38% to $1.55. The market value of their outstanding shares is at $57.7 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) shares increased by 8.37% to $3.75. The market value of their outstanding shares is at $118.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock declined by 29.6% to $0.01 during Friday's after-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock fell 15.69% to $4.14. The market value of their outstanding shares is at $3.0 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 11.63% to $0.38. The market value of their outstanding shares is at $1.8 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares fell 10.53% to $5.44. The market value of their outstanding shares is at $102.1 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 8.74% to $0.94. The company's market cap stands at $8.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 8.44% to $0.44. The market value of their outstanding shares is at $8.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTMD

INTS

KYMR

LGMK

LQDA

PSTV

RSLS

SLXN

Earnings

Earnings Misses

News

Ironwood Pharmaceuticals Q1 Adj. EPS $(0.14) Misses $(0.05) Estimate, Sales $41.14M Miss $45.98M Estimate

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares moved upwards by 67.4% to $0.02 during Tuesday's pre-market session. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares increased by 39.22% to $39.65. The company's market cap stands at $8.8 billion. </li>
<li>LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) stock rose 19.83% to $7.31. The company's market cap stands at $325.9 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock increased by 15.71% to $0.07. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) stock increased by 15.61% to $11.7. The company's market cap stands at $250.1 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 14.14% to $1.07. The market value of their outstanding shares is at $187.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares decreased by 20.7% to $1.0 during Tuesday's pre-market session. The company's market cap stands at $34.5 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 14.51% to $0.31. The company's market cap stands at $10.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 14.06% to $0.25. The market value of their outstanding shares is at $3.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock fell 13.45% to $5.15. The company's market cap stands at $78.4 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock declined by 11.32% to $0.86. The company's market cap stands at $137.7 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 9.16% to $3.31. The market value of their outstanding shares is at $85.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AARD

CYCC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ITRM

LFMD

PTPI

RLMD

SNTI

TVGN

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Guidance

Ironwood Pharmaceuticals Raises 2025 Adj. EBITDA Guidance To Over $105M

Wells Fargo analyst Mohit Bansal downgrades Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) from Overweight to Equal-Weight and lowers the price target from $7 to $1.

Downgrades

Price Target

Analyst Ratings

Wells Fargo Downgrades Ironwood Pharmaceuticals to Equal-Weight, Lowers Price Target to $1

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Dan Levy downgraded the rating for General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Overweight to Equal-Weight and lowered the price target from $70 to $40. General Motors shares closed at $45.14 on Monday. <a href="https://www.benzinga.com/quote/GM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Michael Ha downgraded HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Neutral and cut the price target from $396 to $336. HCA Healthcare shares closed at $340.62 on Monday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Amy Li downgraded the rating for Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) from Buy to Hold and cut the price target from $8 to $0.7. Ironwood Pharmaceuticals shares closed at $0.6479 on Monday. <a href="https://www.benzinga.com/quote/IRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Catherine Novack downgraded the rating for Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) from Buy to Hold. Rallybio shares closed at $0.2702 on Monday. <a href="https://www.benzinga.com/quote/RLYB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Dan Levy downgraded Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Overweight to Equal-Weight and cut the price target from $22 to $14. Mobileye Global shares closed at $12.94 on Monday.  <a href="https://www.benzinga.com/quote/MBLY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-1024x587.png" alt="" class="wp-image-872090" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44806916/citigroup-bank-of-america-and-3-stocks-to-watch-heading-into-tuesday">Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Trading Ideas

MBLY

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Jefferies analyst Amy Li downgrades Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) from Buy to Hold and lowers the price target from $8 to $0.7.

Jefferies Downgrades Ironwood Pharmaceuticals to Hold, Lowers Price Target to $0.7

Leerink Partners analyst Faisal Khurshid maintains Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) with a Market Perform and lowers the price target from $3 to $1.

Leerink Partners Maintains Market Perform on Ironwood Pharmaceuticals, Lowers Price Target to $1

WIIM

Ironwood Pharmaceuticals shares are trading lower after the company announced that the FDA wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.

Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome <a href="https://www.benzinga.com/general/health-care">with intestinal failure</a>.
Ironwood has engaged Goldman Sachs Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44785200/ironwood-pharmaceuticals-provides-clinical-and-regulatory-update-on-apraglutide" rel="noreferrer noopener">explore strategic alternatives</a>.
Apraglutide is a once-weekly, long-acting synthetic GLP-2 analog with the potential to treat rare gastrointestinal diseases.
In preparation for the new drug application (NDA) submission, pharmacokinetic analysis indicated that the exposure and dose delivered in the STARS Phase 3 trial were lower than planned due to dose <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37399087/why-is-gastrointestinal-healthcare-focused-ironwood-pharmaceuticals-stock-sinking-on-thursday" rel="noreferrer noopener">preparation and administration</a>.
Based on the strength of the STARS Phase 3 results, Ironwood believed there was a regulatory path forward.
Following a recent dialogue with the FDA, the company said a confirmatory Phase 3 trial is needed to seek approval.
Ironwood plans to work with the FDA on designing a confirmatory Phase 3 trial and the regulatory path forward.
Apraglutide generated strong safety and efficacy data in the STARS Phase 3 trial. Following an analysis of long-term extension trial data, 27 apraglutide-dosed patients dependent on parenteral support achieved enteral autonomy, which is the ultimate goal for these patients. Consistent with FDA discussions, Ironwood plans to continue the long-term extension trial and believes the data from the STARS trial will continue to be an integral part of an NDA submission package.
&#8220;We are disappointed in this outcome,&#8221; Tom McCourt, CEO of Ironwood. 
Apraglutide has the potential to provide &#8220;tremendous value to patients with SBS-IF who suffer from increased mortality and reduced quality of life,&#8221; McCourt added.
Ironwood initiated the rolling new drug application to the FDA for apraglutide for SBS, with submission completion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44002403/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-results-achieves-2024-financial" rel="noreferrer noopener">expected in Q3 2025</a>.
Price Action: IRWD stock is down 30.28% at 66 cents at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44775286/tariffs-may-have-mixed-effects-on-carmax-may-boost-used-car-demand-due-to-pricier-new-cars-analyst" target="_blank" rel="noreferrer noopener">Tariffs May Have Mixed Effects On Carmax, May Boost Used Car Demand Due To Pricier New Cars: Analyst</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 68.6% to $0.04 during Monday's regular session. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 54.25% to $0.19. The market value of their outstanding shares is at $5.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 39.56% to $5.08. The company's market cap stands at $229.1 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) shares increased by 34.27% to $18.8. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock increased by 31.14% to $3.79. The company's market cap stands at $196.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock increased by 29.1% to $0.86. The company's market cap stands at $69.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 30.0% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $105.9 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 22.36% to $0.24. The market value of their outstanding shares is at $19.9 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 21.84% to $5.07. The market value of their outstanding shares is at $275.5 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares decreased by 17.92% to $0.38. The company's market cap stands at $4.2 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares declined by 17.62% to $1.73. The company's market cap stands at $16.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 17.58% to $0.95. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

APDN

BFRG

IMAB

MTSR

STSS

THRD

WGRX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.
The Dow traded up 0.43% to 40,384.20 while the NASDAQ gained 0.33% to 16,778.86. The S&amp;P 500 also rose, gaining, 0.55% to 5,392.71.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/44787507/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Information technology shares surged by 2% on Monday.
In trading on Monday, consumer discretionary shares rose by just 0.6%.
Top Headline
M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) posted weaker-than-expected earnings for its first quarter.
M&amp;T Bank reported quarterly earnings of $3.38 per share which missed the analyst consensus estimate of $3.40 per share. The company reported quarterly sales of $2.31 billion which missed the analyst consensus estimate of $2.34 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares shot up 67% to $0.2251 after the company announced its merger agreement with 20/20 Biolabs. The closing equity value of the combined companies is $99 million.</li>
<li>Shares of USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>)got a boost, surging 40% to $11.64.</li>
<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) shares were also up, gaining 39% to $2.7049 after receiving an acquisition proposal from Future Pak. Soleus Capital has issued a letter to shareholders stating that the deal is in their best interest.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) shares dropped 34% to $0.6215. Ironwood said feedback from the FDA indicates that confirmatory Phase 3 trial is needed to seek approval of Apraglutide for patients with SBS with intestinal failure.</li>
<li>Shares of Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) were down 28% to $1.0996. Mixed Martial Arts Group shares jumped 92% on Friday after the company announced it had entered into a non-dilutive and unsecured $2 million revolving loan agreement.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) was down, falling 8% to $17.36. Truist Securities analyst Michael Swartz maintained MarineMax with a Buy and lowered the price target from $38 to $26.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $60.99 while gold traded down 0.8% at $3,219.90.
Silver traded up 0.3% to $32.020 on Monday, while copper rose 1.3% to $4.5830.
Euro zone
European shares were higher today. The eurozone's STOXX 600 jumped 2.52%, Germany's DAX 40 gained 2.80% and France's CAC 40 climbed 2.40%. Spain's IBEX 35 Index surged 2.30%, while London's FTSE 100 rose 2.00%.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 1.18%, China's Shanghai Composite gaining 0.76% and Hong Kong's Gang Seng index rising 2.40%.
Economics
Data on consumer inflation expectations will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

THTX

USAR

Crude Oil Moves Lower; M&T Bank Earnings Miss Views

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 2% on Monday.
The Dow traded up 0.99% to 40,610.00 while the NASDAQ gained 2.02% to 17,062.41. The S&amp;P 500 also rose, gaining, 1.48% to 5,442.94.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/44787507/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Information technology shares surged by 2.2% on Monday.
In trading on Monday, consumer staples shares rose by just 0.5%.
Top Headline
The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) posted better-than-expected earnings for its first quarter.
Goldman Sachs reported quarterly earnings of $14.12 per share which beat the analyst consensus estimate of $12.35 per share. The company reported quarterly sales of $15.06 billion which beat the analyst consensus estimate of $14.81 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares shot up 92% to $0.2611 after the company announced its merger agreement with 20/20 Biolabs. The closing equity value of the combined companies is $99 million.</li>
<li>Shares of Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>)got a boost, surging 62% to $0.0404.</li>
<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) shares were also up, gaining 45% to $2.8250 after receiving an acquisition proposal from Future Pak. Soleus Capital has issued a letter to shareholders stating that the deal is in their best interest.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) shares dropped 36% to $0.6007. Ironwood said feedback from the FDA indicates that confirmatory Phase 3 trial is needed to seek approval of Apraglutide for patients with SBS with intestinal failure.</li>
<li>Shares of Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) were down 28% to $1.0996. Mixed Martial Arts Group shares jumped 92% on Friday after the company announced it had entered into a non-dilutive and unsecured $2 million revolving loan agreement.</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) was down, falling 26% to $1.5874 after jumping 62% on Friday.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $61.95 while gold traded down 0.9% at $3,214.10.
Silver traded down 0.4% to $31.770 on Monday, while copper rose 1.4% to $4.5840.
Euro zone
European shares were higher today. The eurozone's STOXX 600 jumped 2.5%, Germany's DAX 40 gained 2.7% and France's CAC 40 climbed 2.5%. Spain's IBEX 35 Index surged 2.1%, while London's FTSE 100 rose 1.9%.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 1.18%, China's Shanghai Composite gaining 0.76% and Hong Kong's Gang Seng index rising 2.40%.
Economics
Data on consumer inflation expectations will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 76.0% to $0.04 during Monday's pre-market session. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares increased by 37.36% to $5.0. The company's market cap stands at $225.5 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares increased by 32.2% to $4.31. The company's market cap stands at $382.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 27.6% to $0.16. The market value of their outstanding shares is at $4.7 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares rose 26.52% to $1.04. The market value of their outstanding shares is at $3.3 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 22.3% to $0.2. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares declined by 17.4% to $6.21 during Monday's pre-market session. The company's market cap stands at $581.3 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 16.45% to $0.79. The market value of their outstanding shares is at $126.4 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares declined by 14.18% to $0.95. The company's market cap stands at $4.1 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 12.67% to $1.24. The company's market cap stands at $3.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 11.7% to $0.26. The company's market cap stands at $1.9 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock declined by 11.61% to $2.21. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTL

GYRE

KTTA

MSPR

PTIX

VERV

VRAX

12 Health Care Stocks Moving In Monday's Pre-Market Session

– Feedback from recent FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed to seek approval –
– Company has engaged Goldman Sachs &amp; Co. LLC to explore strategic alternatives –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ironwoodpharma.com%2F&amp;esheet=54237597&amp;newsitemid=20250414687154&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=1ac4b24b2b9c6afb025e8a0341d2a3d4">Ironwood Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral support. While continuing to advance apraglutide, Ironwood has engaged Goldman Sachs &amp; Co. LLC to explore strategic alternatives for the company to maximize value for stockholders.

Ironwood Says Feedback From FDA Indicates That Confirmatory Phase 3 Trial Is Needed To Seek Approval Of Apraglutide For Patients With SBS With Intestinal Failure

Ironwood Pharmaceuticals Receives Letter Of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

<ul>
<li>Ironwood 2025 Financial Guidance. Ironwood continues to expect:</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
2025 Guidance
(February 2025)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">U.S. LINZESS Net Sales</td>
<td colspan="1" rowspan="1">
$800 - $850 million
High single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue1</td>
<td colspan="1" rowspan="1">$260 - $290 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA2</td>
<td colspan="1" rowspan="1">&gt;$85 million</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">1 Ironwood's U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood's commercial expenses related to sales of LINZESS in the U.S. The FY2025 total revenue guidance accounts for the impact of the reduction to Ironwood's commercial expenses and corresponding reimbursement from AbbVie due to Ironwood's strategic reorganization.</td>
</tr>
</tbody>
</table>
</figure>

Ironwood Pharmaceuticals 2025 Outlook: Expects Revenue Of $260M–$290M Vs. $287.583M Est., Sees Adjusted EBITDA Above $85M

Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.08 by 75 percent. The company reported quarterly sales of $90.55 million which missed the analyst consensus estimate of $93.82 million by 3.49 percent. This is a 22.98 percent decrease over sales of $117.55 million the same period last year.

Ironwood Pharmaceuticals Q4 2024 Adj EPS $0.02 Misses $0.08 Estimate, Sales $90.55M Miss $93.82M Estimate

Press Releases

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Millrose Properties Set to Join S&P SmallCap 600

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Comments

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (IRWD) Opciones

Ironwood Pharmaceuticals (NASDAQ:IRWD) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL